Inluriyo Tablet, Film Coated
Product Images NDC 0002-1717

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Inluriyo (NDC 0002-1717). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eli Lilly And Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Package Label – Inluriyo 200 mg 56 Count Bottle (Inluriyo 200mg Label 56ct 2397)

Label for Inluriyo (imlunestrant) 200 mg film-coated tablets by Eli Lilly and Company. The label includes dosage strength, quantity of 56 tablets, storage instructions, and warnings about seal integrity. Manufactured in the USA with product origin Ireland.*

FDA Label Image

Chemical Structure (Inluriyo Uspi Chem V1)

Chemical structure diagram of imlunestrant depicting its molecular framework including aromatic rings, fluorine atoms, and functional groups arranged to represent the active ingredient shown in the product data for Inluriyo tablets.*

FDA Label Image

Figure 1 (Inluriyo Uspi Fig1 V1)

This is a Kaplan-Meier curve depicting progression-free survival (%) over time (months) comparing INLURIYO (imlunestrant) with Fulvestrant or Exemestane. The graph shows patient numbers at risk for each treatment group over the study period up to about 30 months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.